These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

528 related items for PubMed ID: 24074707

  • 1. [HBeAg seroconversion achieved by sequential peginterferon alfa-2a therapy in chronic hepatitis B patients with unsatisfactory end point following entecavir treatment].
    Chen XF, Chen XP, Ma XJ, Chen WL, Luo XD, Liao JY.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Jul; 21(7):502-5. PubMed ID: 24074707
    [Abstract] [Full Text] [Related]

  • 2. [Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].
    Zhu YY, Wu YL, Chen J, Zheng Q, Dong J, Jiang JJ.
    Zhonghua Gan Zang Bing Za Zhi; 2012 Oct; 20(10):737-41. PubMed ID: 23207332
    [Abstract] [Full Text] [Related]

  • 3. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
    Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M.
    J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    Luo XD, Chen XF, Zhou Y, Chen XP.
    J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
    [Abstract] [Full Text] [Related]

  • 6. [Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].
    Ji YJ, Li FF, Ren WH, Zhu YH, Qin CY.
    Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):335-9. PubMed ID: 24025132
    [Abstract] [Full Text] [Related]

  • 7. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B.
    Hsu CW, Su WW, Lee CM, Peng CY, Chuang WL, Kao JH, Chu HC, Huang YH, Chien RN, Liaw YF.
    J Formos Med Assoc; 2018 Jul; 117(7):588-597. PubMed ID: 29456079
    [Abstract] [Full Text] [Related]

  • 8. [Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a].
    Luo XD, Chen XP, Chen R, Chen XF, Huang J.
    Zhonghua Gan Zang Bing Za Zhi; 2016 Apr; 24(4):241-5. PubMed ID: 27470620
    [Abstract] [Full Text] [Related]

  • 9. A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B.
    Xie Q, Zhou H, Bai X, Wu S, Chen JJ, Sheng J, Xie Y, Chen C, Chan HL, Zhao M.
    Clin Infect Dis; 2014 Dec 15; 59(12):1714-23. PubMed ID: 25190434
    [Abstract] [Full Text] [Related]

  • 10. [Analysis of the factors for predicting the outcomes of interferon-α and entecavir treatments for chronic hepatitis B with positive HBeAg].
    Xie Z, Zhou F, Zhou Y.
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun 15; 33(6):878-81. PubMed ID: 23803202
    [Abstract] [Full Text] [Related]

  • 11. Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir.
    Sonneveld MJ, Zoutendijk R, Hansen BE, Janssen HL.
    Antivir Ther; 2012 Jun 15; 17(8):1605-8. PubMed ID: 22898565
    [Abstract] [Full Text] [Related]

  • 12. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ, Yu YQ, Chen SL, Fan P, Shao LY, Chen JZ, Li CS, Yi B, Chen WC, Xie SY, Mao XN, Zou HH, Zhang WH.
    Antimicrob Agents Chemother; 2015 Jul 15; 59(7):4121-8. PubMed ID: 25941216
    [Abstract] [Full Text] [Related]

  • 13. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
    Cao ZH, Ma LN, Zhang HW, Liu YL, Chen XY.
    J Dig Dis; 2013 Aug 15; 14(8):446-50. PubMed ID: 23615131
    [Abstract] [Full Text] [Related]

  • 14. [Efficacy and safety of peginterferon alfa-2a (40 kd) plus adefovir for 96 weeks in HBeAg-negative chronic hepatitis B patients].
    Cao ZH, Ma LN, Liu YL, Jin Y, He ZM, Lu JF, Zhang YH, Chen XY.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Jul 15; 21(7):498-501. PubMed ID: 24074706
    [Abstract] [Full Text] [Related]

  • 15. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J, Jones J, Takeda A, Davidson P, Price A.
    Health Technol Assess; 2006 Aug 15; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [Abstract] [Full Text] [Related]

  • 16. [Optimal treatment regimen for patients with HBeAg-positive chronic hepatitis B after suboptimal response to 24 weeks of Peg-IFN α-2a].
    Luo XD, Chen XP, Chen XF.
    Zhonghua Gan Zang Bing Za Zhi; 2017 Dec 20; 25(12):896-901. PubMed ID: 29325289
    [Abstract] [Full Text] [Related]

  • 17. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study.
    Wu FP, Yang Y, Li M, Liu YX, Li YP, Wang WJ, Shi JJ, Zhang X, Jia XL, Dang SS.
    World J Gastroenterol; 2020 Apr 07; 26(13):1525-1539. PubMed ID: 32308352
    [Abstract] [Full Text] [Related]

  • 18. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z, Deng H, Zhao Q, Zheng Y, Peng L, Lin C, Zhao Z, Gao Z.
    Eur J Gastroenterol Hepatol; 2013 Oct 07; 25(10):1165-9. PubMed ID: 23571612
    [Abstract] [Full Text] [Related]

  • 19. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study).
    Brouwer WP, Xie Q, Sonneveld MJ, Zhang N, Zhang Q, Tabak F, Streinu-Cercel A, Wang JY, Idilman R, Reesink HW, Diculescu M, Simon K, Voiculescu M, Akdogan M, Mazur W, Reijnders JG, Verhey E, Hansen BE, Janssen HL, ARES Study Group.
    Hepatology; 2015 May 07; 61(5):1512-22. PubMed ID: 25348661
    [Abstract] [Full Text] [Related]

  • 20. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W, Yuan H, Mao XR, Deng YD, Chen L.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar 07; 21(3):184-8. PubMed ID: 23967738
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.